Taysha Gene Therapies Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020
Net Income	-111.57	-166.01	-174.52	-60.01
Depreciation & Amortization	2.55	2.49	0.49	0.01
Share-Based Compensation	7.91	18.04	18.18	3.35
Other Operating Activities	28.09	57.09	38.81	25.92
Operating Cash Flow	-73.02	-88.39	-117.04	-30.73
Capital Expenditures	-3.87	-20.62	-15.3	-0.08
Other Investing Activities	-3.48	-4.31	-6.25	-9
Investing Cash Flow	-7.35	-24.93	-21.55	-9.08
Share Issuance / Repurchase	140.86	53.5	0	165.85
Debt Issued / Paid	-3.85	0	39.96	0
Other Financing Activities	-0.62	-1.4	-0.87	125.21
Financing Cash Flow	136.39	52.1	39.08	291.06
Net Cash Flow	56.02	-61.22	-99.51	251.25
Free Cash Flow	-76.89	-109.01	-132.35	-30.81
Free Cash Flow Margin	-497.62%	-4356.87%	-	-
Free Cash Flow Per Share	-0.66	-2.48	-3.52	-1.74

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).